NeuroPace (NPCE) EBITDA Margin Growth (1y) (2021 - 2026)
NeuroPace (NPCE) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -497.00 |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 670.00 |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 301.00 |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 546.00 |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 264.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 595.00 |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 89.00 |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -247.00 |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 146.00 |
| 10 | NeuroPace | 479.51 Mn | 427.81 Mn | 18.91 Mn | 1,946.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,946.00 |
| Mar 31, 2026 | -238.00 |
| Dec 31, 2025 | 1,037.00 |
| Sep 30, 2025 | 1,064.00 |
| Jun 30, 2025 | 334.00 |
| Mar 31, 2025 | 1,878.00 |
| Dec 31, 2024 | 1,102.00 |
| Sep 30, 2024 | 1,607.00 |
| Jun 30, 2024 | 1,522.00 |
| Mar 31, 2024 | 1,585.00 |
| Dec 31, 2023 | 4,905.00 |
| Sep 30, 2023 | 5,519.00 |
| Jun 30, 2023 | 6,002.00 |
| Mar 31, 2023 | 2,834.00 |
| Dec 31, 2022 | 489.00 |
| Sep 30, 2022 | -3,103.00 |
| Jun 30, 2022 | -7,113.00 |
| Mar 31, 2022 | -5,129.00 |
| Dec 31, 2021 | -5,425.00 |
| Sep 30, 2021 | -5,125.00 |